Literature DB >> 1970770

The metabolism and disposition of 14C-fenofibrate in human volunteers.

A Weil1, J Caldwell, M Strolin-Benedetti.   

Abstract

The metabolic fate of a single dose of 14C-fenofibrate has been studied in a panel of eight healthy volunteers (four males and four females). In 7 days, a total of 84% of the administered dose was recovered, with 59% in the urine and 25% in the feces. The majority of the urinary 14C was excreted within 24 hr, whereas the bulk of the fecal 14C was recovered over the first 3 days after dosing. The major urinary metabolite was the ester glucuronide of fenofibric acid, accompanied by much smaller amounts of fenofibric acid and the benzhydrol and its glucuronide. The principal compound in feces was unchanged fenofibrate, together with smaller quantities of fenofibric acid and polar unknown metabolite(s). Experiments on the stability of fenofibryl glucuronide showed it to be less reactive than most ester glucuronides.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970770

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Quantifying In Vivo Luminal Drug Solubilization -Supersaturation-Precipitation Profiles to Explain the Performance of Lipid Based Formulations.

Authors:  Yusuke Tanaka; Erin Tay; Tri-Hung Nguyen; Christopher J H Porter
Journal:  Pharm Res       Date:  2020-02-03       Impact factor: 4.200

Review 2.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.

Authors:  J A Balfour; D McTavish; R C Heel
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

3.  PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.

Authors:  N Marx; G K Sukhova; T Collins; P Libby; J Plutzky
Journal:  Circulation       Date:  1999-06-22       Impact factor: 29.690

4.  PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.

Authors:  Nikolaus Marx; Bettina Kehrle; Klaus Kohlhammer; Miriam Grüb; Wolfgang Koenig; Vinzenz Hombach; Peter Libby; Jorge Plutzky
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

5.  Distribution of fenofibric acid in lipoprotein fractions of patients.

Authors:  M Nobilis; J Kvetina; P Anzenbacher; T Vontor; D Svoboda; M Brátová; D Solichová; Z Zadák; V Bláha; J Vlcek
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

6.  New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS.

Authors:  A Liu; Y Chen; Z Yang; Y Feng; W Rui; W Luo; Y Liu; F J Gonzalez; R Dai
Journal:  Xenobiotica       Date:  2009-04       Impact factor: 1.908

7.  Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.

Authors:  Aiming Liu; Andrew D Patterson; Zongtao Yang; Xinying Zhang; Wei Liu; Fayang Qiu; He Sun; Kristopher W Krausz; Jeffrey R Idle; Frank J Gonzalez; Renke Dai
Journal:  Drug Metab Dispos       Date:  2009-02-27       Impact factor: 3.922

8.  Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic?

Authors:  H F Liu; M Vincent-Viry; M M Galteau; R Guéguen; J Magdalou; A Nicolas; P Leroy; G Siest
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential.

Authors:  J Stalinska; E Zimolag; N A Pianovich; A Zapata; A Lassak; M Rak; M Dean; D Ucar-Bilyeu; D Wyczechowska; F Culicchia; L Marrero; L Del Valle; J Sarkaria; F Peruzzi; B S Jursic; K Reiss
Journal:  Transl Oncol       Date:  2019-05-09       Impact factor: 4.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.